Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Neoplasms 4Carcinoma 4Carcinoma, Non-Small-Cell Lung 3Ovarian Neoplasms 2Neoplasm Metastasis 2Melanoma 2Peritoneal Neoplasms 1Pancreatic Neoplasms 1Lung Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1

Interventions

Paclitaxel 328Carboplatin 323Bevacizumab 171Gemcitabine 106liposomal doxorubicin 104pembrolizumab 101Cyclophosphamide 96Topotecan 94olaparib 92Cisplatin 92niraparib 69Docetaxel 57Taxes 52Doxorubicin 51Drug Therapy 45fludarabine 40Filgrastim 39Nivolumab 37Magnetic Resonance Spectroscopy 34Surveys and Questionnaires 33Specimen Handling 33Etoposide 32Hyperthermic Intraperitoneal Chemotherapy 31Blood Specimen Collection 29Immunoglobulin G 27Disulfides 27Peripheral Blood Stem Cell Transplantation 26Cytoreduction Surgical Procedures 25Albumin-Bound Paclitaxel 25durvalumab 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Ovarian Neoplasms × volociximab × Clear all
NCT00635193 2013-01-18

Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin)

AbbVie

Phase 1/2 Completed
138 enrolled
Gynecologic

Ovarian Neoplasms

NCT00516841 2012-08-23

A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer

Facet Biotech

Phase 2 Terminated
16 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡